2023-07-10 06:01:03 ET
- Late-clinical stage biotechnology company, Nanobiotix ( NASDAQ: NBTX ) stock price surges 54% during pre-market hours as the company enters a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV.
- Janssen Pharmaceutica NV is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.
- Under the terms of the license agreement, in collaboration with the Interventional Oncology R&D Unit at Johnson & Johnson, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3.
- Nanobiotix will receive near term cash and operational support valued up to $6M. This includes an upfront cash licensing fee of $30M, and in-kind regulatory and development support for study NANORAY-312 valued at up to $30M that Janssen may provide at its sole discretion.
For further details see:
Nanobiotix up 54% on licensing agreement for development of Radioenhancer NBTXR3